Table 3.

s-RNY1-5p level according to high sensitive C-reactive protein (hs-CRP) levels, apolipoprotein B (ApoB) levels, statin therapy, and fibrate therapy and case–control (CC) status

CRP (mg/L)	CC	(s-RNY1-5p)1/7	CC effect	hs-CRP effect	CC × hs-CRP interaction
<6	Case (n = 121)	1.30 (0.17)	0.001	0.03	0.72
≥6	Case (n = 142)	1.34 (0.18)
<6	Control (n = 449)	0.95 (0.18)
≥6	Control (n = 65)	0.98 (0.20)
ApoB (g/L)	CC	(s-RNY1-5p)1/7	CC effect	ApoB effect	CC × ApoB interaction
<1.02	Case (n = 115)	1.30 (0.18)	0.001	0.001	0.79
≥1.02	Case (n = 148)	1.35 (0.17)
<1.02	Control (n = 200)	0.92 (0.19)
≥1.02	Control (n = 314)	0.97 (0.19)
Statin therapy	CC	(s-RNY1-5p)1/7	CC effect	statin effect	CC × statin interaction
No	Case (n = 115)	1.34 (0.18)	0.001	0.15	0.78
Yes	Case (n = 148)	1.31 (0.18)
No	Control (n = 428)	0.95 (0.19)
Yes	Control (n = 86)	0.93 (0.20)
Fibrate therapy	CC	(s-RNY1-5p)1/7	CC effect	fibrate effect	CC × fibrate interaction
No	Case (n = 242)	1.33 (0.17)	0.001	0.21	0.46
Yes	Case (n = 21)	1.28 (0.19)
No	Control (n = 472)	0.95 (0.19)
Yes	Control (n = 42)	0.94 (0.18)